Finally, ablation of Nfib using CRISPR‐Cas 9 technology also increased tumour latency, decreased the number of circulating tumour cells and prolonged overall survival of BALB/c mice orthotopically injected with the highly metastatic 4T1 mammary cancer cells (Appendix Fig 2A–D). This evidence concerns the gene NFIB and breast cancer.